- Home
- SBXD vs ACIU Comparison
SBXD vs ACIU Comparison
Compare SBXD & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBXD
- ACIU
- Stock Information
- Founded
- SBXD 2024
- ACIU 2003
- Country
- SBXD United States
- ACIU Switzerland
- Employees
- SBXD N/A
- ACIU N/A
- Industry
- SBXD
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- SBXD
- ACIU Health Care
- Exchange
- SBXD NYSE
- ACIU Nasdaq
- Market Cap
- SBXD 257.1M
- ACIU 247.4M
- IPO Year
- SBXD 2024
- ACIU 2016
- Fundamental
- Price
- SBXD $10.21
- ACIU $1.47
- Analyst Decision
- SBXD
- ACIU Strong Buy
- Analyst Count
- SBXD 0
- ACIU 2
- Target Price
- SBXD N/A
- ACIU $12.00
- AVG Volume (30 Days)
- SBXD 94.3K
- ACIU 190.6K
- Earning Date
- SBXD 01-01-0001
- ACIU 05-12-2025
- Dividend Yield
- SBXD N/A
- ACIU N/A
- EPS Growth
- SBXD N/A
- ACIU N/A
- EPS
- SBXD N/A
- ACIU N/A
- Revenue
- SBXD N/A
- ACIU $30,136,397.00
- Revenue This Year
- SBXD N/A
- ACIU N/A
- Revenue Next Year
- SBXD N/A
- ACIU $676.94
- P/E Ratio
- SBXD $49.77
- ACIU N/A
- Revenue Growth
- SBXD N/A
- ACIU 84.51
- 52 Week Low
- SBXD $9.95
- ACIU $1.43
- 52 Week High
- SBXD $10.40
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- SBXD N/A
- ACIU 24.24
- Support Level
- SBXD N/A
- ACIU $1.45
- Resistance Level
- SBXD N/A
- ACIU $1.54
- Average True Range (ATR)
- SBXD 0.00
- ACIU 0.11
- MACD
- SBXD 0.00
- ACIU 0.01
- Stochastic Oscillator
- SBXD 0.00
- ACIU 10.20
About SBXD SILVERBOX CORP IV
SilverBox Corp IV is a blank check company.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.